Schaefer et al. 1 (referred to as Study_1) recently presented the provocative conclusion that CRISPR-Cas9 nuclease can induce many unexpected off-target mutations across the genome that arise from the sites with poor homology to the gRNA. As Wilson et al. 2 pointed out, however, the selection of a co-housed mouse as the control is insufficient to attribute the observed mutation differences between the CRISPR-treated mice and control mice. Therefore, the causes of these mutations need to be further investigated. In 2015, Iyer et al. 3 (referred to as Study_2) used Cas9 and a pair of sgRNAs to mutate the Ar gene in vivo and off-target mutations were investigated by comparison the control mice and the offspring of the modified mice. After analyzing the whole genome sequencing (WGS) of the offspring and the control mice, they claimed that off-target mutations are rare from CRISPR-Cas9 engineering. Notably, their study only focused on indel off-target mutations. We re-analyzed the WGS data of these two studies and detected both single nucleotide variants (SNVs) and indel mutations.
Because these two studies draw relatively opposite conclusions on the off-targeting of the CRISPR system on the whole genome, the origins or causes of the mutations need to be cautiously examined. Here we performed a computationally evolutionary investigation ( Figure 1a) to re-analyze the WGS data of these two studies with a direct comparison of the experiment design and analysis results ( Figure 1a ) in Study_1 are not typically germline-like, while for Study_2, the detected SNVs are in fact germline mutations.
Thousands of genomic mutations were found from both studies based on our computational framework (Supplementary Table 2 ). Following our strict criteria to filter SNVs with low mutation frequency and indels overlapping with the UCSC Genome Browser 5, 6 short tandem repeat, we confirmed a low number of so-called unexpected mutations claimed in Study_1 1 (Supplementary Table 2 ). A great deal of filtered mutations are potentially false positives arising from spontaneous mutations, sequencing and Burrows-Wheeler Aligner(BWA) 7 alignment errors. This leads us believe that the calling of CRISPR-induced mutations especially indels should be carefully performed to avoid false positives. We integrated two computational methods to infer the putative origins of these detected SNVs, by (1) quantitatively analyzing the similarity of the mutation pattern [8] [9] [10] [11] (Supplementary Table 3 ) between the reference germline SNVs (derived from well-curated public databases 5, 9 ; Figure 1a and Supplementary Notes) and the detected SNVs derived from Study_1 and Study_2 followed our re-analysis pipeline. The rationale is that for a particular organism (e.g., mouse), its germline mutation pattern should be evolutionarily conserved; (2) we applied a hypergeometric distribution to test the difference of mutation heterozygosity between the sample-level germline SNVs (detected using GATK HaplotypeCaller; Figure 1a and Supplementary Notes) and the detected SNVs. As seen in the heatmap (Figure 1b) , the detected SNV mutation pattern correctly cluster the samples from different studies. In addition, the mutation pattern of samples from Study_2 highly correlated with the reference dbSNP germline mutation pattern (R 2~0 .85, P-value <2.2e-16), while the correlation between the samples from Study_1 and the reference dbSNP germline was weaker (R 2~0 .55, P-value~1e-10). Although the correlation of mutation pattern in either study with germline at evolution scale are relatively low, we found that the samples from Study_2 correlated stronger with germline mutation pattern than those of samples from Study_1.
The heterozygosity of the so-called unexpected SNVs of the samples in Study_1 was 67.2% and 70.4%, respectively (Figure 1c) , while that of the sample-level germline SNVs was much lower (Figure 1c) . We reasoned that if all the detected SNVs were germline, the heterozygosity of such SNVs would be nearly identical to that of the sample-level germline SNVs. Our statistical test, however, indicates a significant difference between the heterozygosity of them (p-value=0; Supplementary Notes), proving that the overall derived mutation pattern in Study_1 is not germline-like. Note that Lareau et al. and Kim et al. 4, 6 recently demonstrated that the two CRISPR-Cas9 treated mice (F03, F05) in Study_1 are actually more closely related to each other genetically than to the control mouse, proving that these mutations are most likely preexisting variants. Our analysis result further presented that there are unusual SNVs arose in Study_1 combined with pre-existing variants, and the overall mutation pattern in vivo are not germline-like. In contrast, in Study_2, we cannot reject the null hypothesis that the detected SNVs were sampled from the germline background. We computationally validated that the majority of the detected mutations in Study_2 are germline, which is consistent with their original notation that off-target somatic mutations are rare in their Cas9-modified mice 3 .
Because the same CRISPR genome-editing technology led to different conclusions in two studies, we performed a direct comparison of these two studies to evaluate the possible causes for the differences (Table 1 and Supplementary Table 1) . First, the experimental protocols differ, where the protocol used in Study_1 is not a routine and well-accepted CRISPR knockout protocol (sgRNA plasmid + Cas9 protein). The potentiality to induce unusual mutation patterns with such protocol are waiting to be further explored. Secondly, the whole genome sequencing of the founder mouse should be performed before CRISPR knockout. The founder genetic variation should be carefully examined in both studies, since such genetic variation, which may contain in the zygotes, can confound the target sites of certain sgRNAs more than others. This information should be integrated into the study for sgRNA selection to ensure safety 12 .
In summary, we demonstrated that the unexpected CRISPR off-target mutation pattern in Study_1 are not typically germline-like. Some of unusual and unidentified mutations may arise in Study_1, but the real reasons remain to be explored. Based on the available data and a direct comparison of the two studies, we presented two possible reasons and future re-analysis directions that may contribute to such different conclusions. To characterize the authentic CRISPR-mediated mutations, we are required to have appropriate controls to rule out other sources of mutations, which will be needed for benchmarking of targeting safety of CRISPR-based gene therapy. 
